219 related articles for article (PubMed ID: 18068276)
1. How much cervical cancer in Australia is vaccine preventable? A meta-analysis.
Brotherton JM
Vaccine; 2008 Jan; 26(2):250-6. PubMed ID: 18068276
[TBL] [Abstract][Full Text] [Related]
2. Human papillomavirus and cervical cancer in Australasia and Oceania: risk-factors, epidemiology and prevention.
Garland SM; Brotherton JM; Skinner SR; Pitts M; Saville M; Mola G; Jones RW
Vaccine; 2008 Aug; 26 Suppl 12():M80-8. PubMed ID: 18945417
[TBL] [Abstract][Full Text] [Related]
3. Annual disease burden due to human papillomavirus 16 and 18 infections in Finland.
Syrjänen KJ
Scand J Infect Dis Suppl; 2009; 108():2-32. PubMed ID: 19939209
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology and prevention of cervical cancer in Indonesia, Malaysia, the Philippines, Thailand and Vietnam.
Domingo EJ; Noviani R; Noor MR; Ngelangel CA; Limpaphayom KK; Thuan TV; Louie KS; Quinn MA
Vaccine; 2008 Aug; 26 Suppl 12():M71-9. PubMed ID: 18945416
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus types in invasive cervical cancer specimens from Turkey.
Usubütün A; Alemany L; Küçükali T; Ayhan A; Yüce K; de Sanjosé S; Font R; Lloveras B; Klaustermeier J; Quint W; Muñoz N; Bosch FX
Int J Gynecol Pathol; 2009 Nov; 28(6):541-8. PubMed ID: 19851201
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus infection and cervical cancer prevention in Japan and Korea.
Konno R; Shin HR; Kim YT; Song YS; Sasagawa T; Inoue M; Park JS
Vaccine; 2008 Aug; 26 Suppl 12():M30-42. PubMed ID: 18945412
[TBL] [Abstract][Full Text] [Related]
7. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
Jenkins D
Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
[TBL] [Abstract][Full Text] [Related]
8. Looking beyond human papillomavirus (HPV) genotype 16 and 18: Defining HPV genotype distribution in cervical cancers in Australia prior to vaccination.
Brotherton JML; Tabrizi SN; Phillips S; Pyman J; Cornall AM; Lambie N; Anderson L; Cummings M; Payton D; Scurry JP; Newman M; Sharma R; Saville M; Garland SM
Int J Cancer; 2017 Oct; 141(8):1576-1584. PubMed ID: 28677147
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of high-risk human papillomavirus type 16/18 infection among women with normal cytology: risk factor analysis and implications for screening and prophylaxis.
Gupta S; Sodhani P; Sharma A; Sharma JK; Halder K; Charchra KL; Sardana S; Singh V; Sehgal A; Das BC
Cytopathology; 2009 Aug; 20(4):249-55. PubMed ID: 19018810
[TBL] [Abstract][Full Text] [Related]
10. Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium.
Arbyn M; Benoy I; Simoens C; Bogers J; Beutels P; Depuydt C
Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):321-30. PubMed ID: 19124515
[TBL] [Abstract][Full Text] [Related]
11. HPV type 18 is more oncopotent than HPV16 in uterine cervical carcinogenesis although HPV16 is the prevalent type in Chennai, India.
Berlin Grace VM
Indian J Cancer; 2009; 46(3):203-7. PubMed ID: 19574671
[TBL] [Abstract][Full Text] [Related]
12. Human papilloma viruses and cancer in the post-vaccine era.
Galani E; Christodoulou C
Clin Microbiol Infect; 2009 Nov; 15(11):977-81. PubMed ID: 19874381
[TBL] [Abstract][Full Text] [Related]
13. New advances in vaccine technology and improved cervical cancer prevention.
Huh WK; Kendrick JE; Alvarez RD
Obstet Gynecol; 2007 May; 109(5):1187-92. PubMed ID: 17470604
[TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus type-distribution in the cervix of Chinese women: a meta-analysis.
Bao YP; Li N; Smith JS; Qiao YL
Int J STD AIDS; 2008 Feb; 19(2):106-11. PubMed ID: 18334063
[TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus genotype distribution in cervical cancer cases in Spain. Implications for prevention.
Alemany L; Pérez C; Tous S; Llombart-Bosch A; Lloveras B; Lerma E; Guarch R; Andújar M; Pelayo A; Alejo M; Ordi J; Klaustermeier J; Velasco J; Guimerà N; Clavero O; Castellsagué X; Quint W; Muñoz N; Bosch FX; de Sanjosé S;
Gynecol Oncol; 2012 Mar; 124(3):512-7. PubMed ID: 22119990
[TBL] [Abstract][Full Text] [Related]
16. [Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].
Bégué P; Henrion R; Blanc B; Girard M; Sancho-Garnier H
Bull Acad Natl Med; 2007 Dec; 191(9):1805-16; discussion 1816-7. PubMed ID: 18663976
[TBL] [Abstract][Full Text] [Related]
17. Can genital-tract human papillomavirus infection and cervical cancer be prevented with a vaccine?
Dillner J; Brown DR
Expert Rev Mol Med; 2004 Apr; 6(9):1-21. PubMed ID: 15096282
[TBL] [Abstract][Full Text] [Related]
18. [Anal cancer and human papillomaviruses: a perspective based on the cervical cancer model].
Monsonego J
Gynecol Obstet Fertil; 2010 Apr; 38(4):250-4. PubMed ID: 20362481
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus subtype 16 is common in Pakistani women with cervical carcinoma.
Khan S; Jaffer NN; Khan MN; Rai MA; Shafiq M; Ali A; Pervez S; Khan N; Aziz A; Ali SH
Int J Infect Dis; 2007 Jul; 11(4):313-7. PubMed ID: 17291804
[TBL] [Abstract][Full Text] [Related]
20. Prospective seroepidemiologic study of human papillomavirus and other risk factors in cervical cancer.
Arnheim Dahlström L; Andersson K; Luostarinen T; Thoresen S; Ögmundsdottír H; Tryggvadottír L; Wiklund F; Skare GB; Eklund C; Sjölin K; Jellum E; Koskela P; Wadell G; Lehtinen M; Dillner J
Cancer Epidemiol Biomarkers Prev; 2011 Dec; 20(12):2541-50. PubMed ID: 21994401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
